上海医药：枸橼酸托法替布缓释片获批准生产

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has received a drug registration certificate for Tocilizumab Sustained-Release Tablets from the National Medical Products Administration, allowing for production approval [1] Group 1: Product Approval - The drug Tocilizumab Sustained-Release Tablets is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [1] - The drug was originally developed by Pfizer and was launched in the United States in 2016 [1] Group 2: Regulatory Process - Shanghai Shiyou Zhongxi submitted the registration application for the drug to the National Medical Products Administration in January 2024, which has been accepted [1] - The drug registration certificate number is 2025S03257 [1] Group 3: Investment and R&D - The company has invested approximately RMB 19.42 million in research and development for this drug [1]